The Mitochondrial and Autosomal Mutation Landscapes of Prostate Cancer

Slides:



Advertisements
Similar presentations
European Urology Focus
Advertisements

The PSA Era is not Over for Prostate Cancer
Alvin Y. Liu, Martine P. Roudier, Lawrence D. True 
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 67, Issue 4, Pages (April 2015)
Volume 52, Issue 1, Pages (July 2007)
Volume 72, Issue 1, Pages (July 2017)
Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.
Volume 69, Issue 4, Pages (April 2016)
Volume 51, Issue 4, Pages (April 2007)
Landscape overview of GENIE dataset.
Volume 52, Issue 3, Pages (September 2007)
Volume 56, Issue 2, Pages (August 2009)
Spatiotemporal Evolution of the Primary Glioblastoma Genome
Volume 67, Issue 4, Pages (April 2015)
Volume 72, Issue 2, Pages (August 2017)
Volume 60, Issue 5, Pages (November 2011)
Volume 53, Issue 4, Pages (April 2008)
Prostate Cancer Detection: A View of the Future
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 2, Issue 4, Pages (April 2008)
Volume 74, Issue 5, Pages (November 2018)
Volume 60, Issue 5, Pages (November 2011)
Shaheen Alanee, Kasmintan Schrader, Kenneth Offit  European Urology 
The Mutational Landscape of Prostate Cancer
Volume 46, Issue 2, Pages (February 2017)
The PSA Era is not Over for Prostate Cancer
European Urology Oncology
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer  Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.
Mark A. Rubin, Gabriele Girelli, Francesca Demichelis  European Urology 
Volume 72, Issue 4, Pages (October 2017)
Leonard S. Marks, Jiaoti Huang  European Urology 
Volume 63, Issue 3, Pages (March 2013)
Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.
The Lethal Clone in Prostate Cancer: Redefining the Index
Volume 68, Issue 6, Pages e134-e135 (December 2015)
Volume 41, Issue 2, Pages (February 2002)
Volume 145, Issue 3, Pages (June 2017)
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
A Tumor Sorting Protocol that Enables Enrichment of Pancreatic Adenocarcinoma Cells and Facilitation of Genetic Analyses  Zachary S. Boyd, Rajiv Raja,
Volume 129, Issue 3, Pages (September 2005)
New Views into the Genetic Landscape of Metastatic Breast Cancer
Volume 71, Issue 5, Pages (May 2017)
Volume 5, Issue 4, Pages e5 (October 2017)
Abdul K. Siraj, Tariq Masoodi, Rong Bu, Shaham Beg, Saif S
Volume 140, Issue 3, Pages e8 (March 2011)
Volume 69, Issue 5, Pages (May 2016)
Longitudinal Study of Recurrent Metastatic Melanoma Cell Lines Underscores the Individuality of Cancer Biology  Zoltan Pos, Tara L. Spivey, Hui Liu, Michele.
Kelsie L. Thu, BSc, Raj Chari, PhD, William W
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Volume 9, Issue 3, Pages (March 2006)
Personalized Medicine: Patient-Predictive Panel Power
Volume 24, Issue 12, Pages e5 (September 2018)
Volume 152, Issue 1, Pages (January 2019)
Volume 155, Issue 4, Pages (November 2013)
Volume 24, Issue 7, Pages (August 2018)
Mapping Cancer Origins
Volume 130, Issue 7, Pages (June 2006)
Volume 10, Issue 6, Pages (December 2006)
Spatiotemporal Evolution of the Primary Glioblastoma Genome
Figure 1. T-cell lymphoma–free survival of untreated and IR-exposed Mlh1−/− mice. Kaplan–Meier survival ... Figure 1. T-cell lymphoma–free survival of.
Brennan Decker, Danielle M. Karyadi, Brian W
Volume 118, Issue 2, Pages (July 2004)
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Figure 1. Identification of three tumour molecular subtypes in CIT and TCGA cohorts. We used CIT multi-omics data ( Figure 1. Identification of.
Volume 2, Issue 3, Pages (March 2016)
Mutational Analysis of Ionizing Radiation Induced Neoplasms
Volume 28, Issue 3, Pages e7 (July 2019)
Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis  Paolo A. Ascierto, Carlo Bifulco, Giuseppe.
Presentation transcript:

The Mitochondrial and Autosomal Mutation Landscapes of Prostate Cancer Johan Lindberg, Ian G. Mills, Daniel Klevebring, Wennuan Liu, Mårten Neiman, Jianfeng Xu, Pernilla Wikström, Peter Wiklund, Fredrik Wiklund, Lars Egevad, Henrik Grönberg  European Urology  Volume 63, Issue 4, Pages 702-708 (April 2013) DOI: 10.1016/j.eururo.2012.11.053 Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 1 Significantly mutated genes in 63 prostate tumors. Center grid: Samples are ordered according to the most frequently mutated genes on a descending scale with priority given to autosomal genes. Color code: grey=no mutation; blue=protein altering single nucleotide variants/insertions and deletions; red=point mutation and deletion; green=point mutation and amplification. Upper grid: Clinical outcome. Color code: black=aggressive disease (prostate-specific antigen [PSA] level >10 ng/ml after surgery), red=biochemical recurrence (PSA range: 0.2–10 ng/ml after surgery), green=nonrecurrent disease, grey=unknown. Due to high similarity between right and left lymph node metastases found in SWE-52, only SWE-52B is presented. To avoid inflation of genes found in primary–metastasis pairs or as high-low frequency mutations in tumor samples from the same prostate, common mutations were assigned only to the tumor tissue that harbored it in highest fraction. MT-ETC=tumors with mutations in any mitochondrial electron transport chain gene. European Urology 2013 63, 702-708DOI: (10.1016/j.eururo.2012.11.053) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 2 Multilevel genomic profiling. (A) The total number of chromosomal breaks compared to the mutation rate for each tumor (number of mutations per megabase of exome sequence). Correlation excludes SWE-37 and SWE-7 with suspected mutations in mismatch repair phenotype (r=0.44, p=0.0015). (B) The total number of chromosomal breaks compared to proliferation score for each tumor. A high proliferation score implies high expression of genes related to the cell-cycle (see Supplementary Text). Tumors are colored according to the scheme in the key; tumor protein p53 (TP53)/speckle-type POZ protein (SPOP) status also is presented. The circles are scaled according to maximum postoperative prostate-specific antigen (PSA) value, as shown in the key. The colors represent the lower limit for respective clinical outcome. The tumors analyzed in this figure constitute the core of 50 primary tumors from which copy number alteration data, and RNA and exome sequencing data were available. European Urology 2013 63, 702-708DOI: (10.1016/j.eururo.2012.11.053) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 3 Estimated fraction of cells harboring single nucleotide variants (SNVs) in relation to the expression of cell cycle genes. Upper panel: The estimated number of cells harboring each SNV (points in the figure) was assessed through a Dirichlet process described by Shah and colleagues [20]. Tumors are sorted after the median number of cells harboring each variant. Color code: black=aggressive disease (prostate-specific antigen [PSA] level >10 ng/ml after surgery), red=biochemical recurrence (PSA range: 0.2–10 ng/ml after surgery), green=nonrecurrent disease, grey=unknown. Bottom panel: A loess line demonstrating the gradual increase in proliferation score as the median proportion of cells increases for each tumor. The tumors analyzed in this figure constitute the core of 50 primary tumors from which which copy number alteration data, and RNA and exome sequencing data were available. Note the two tumor samples with a suspected mutations in mismatch repair phenotype, SWE-37 and SWE-7. SWE-37 harbored a majority of low-frequency mutations, a pattern also present in other tumors, whereas SWE-7 carried a more even spectrum of frequencies despite the high mutation rate, which was not observed in any other tumor sample. European Urology 2013 63, 702-708DOI: (10.1016/j.eururo.2012.11.053) Copyright © 2012 European Association of Urology Terms and Conditions